Best Life Sciences Platforms and Tools Companies in Germany
The 539 best Life Sciences Platforms and Tools companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Singleron.
Germany's Life Sciences Platforms and Tools sector is the subject of this directory, ranking 539 tracked companies by disclosed equity funding and recent momentum. Total disclosed funding sits at $756M across the cohort, with no unicorns yet, though the market these companies are chasing is substantial. The global Life Sciences Platforms and Tools market was valued at roughly $89.4B in 2020 and is forecast to reach $183.8B by 2027 at a 10.8% CAGR, driven by advances in quantitative accuracy, mass spectrometry resolution, and information sciences. Regulatory complexity remains a real structural headwind, and you'd be wrong to underestimate how much that shapes funding timelines here.
At the top of our funding table, Pl Bioscience and Leniobio each pulled in $13M, with Cellbox Solutions at $7M behind them. These aren't massive rounds by global standards, and I think that's the honest story: Germany's ecosystem here is early-stage, grant-heavy, and institution-backed, with Europa, HTGF, and Kfw dominating the investor list. So the opportunity gap is real. Digital engagement in adjacent health and life sciences tools is accelerating fast, with median app install growth running around 43% year-over-year across healthcare and life sciences platforms. The capital is thin but the demand signal is loud.
- Precedence Research
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Germany
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Singleron Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | $84M | 55 mo ago | Series B | — | 2018 | Jing Zhou Co-Founder | — | — |
| 2 | Cellzome Small-molecule kinase targeted drugs to treat inflammatory diseases | $78M | 210 mo ago | Acquired | 90 | 2000 | — | 202 patents Enzyme‑focused drug discovery: modulators/inhibitors of gamma‑secretase, PI3K, tankyrase. | — |
| 3 | Ingenium Pharamceutical Discovering drug targets through Deductive Genomics | $71M | 242 mo ago | Acquired | 41 | 1999 | John Watkins President & CEO | — | — |
| 4 | Indivumed Specimen biobank, Drug and biomarker service provider | $48M | 101 mo ago | Funding Raised | 178 | 2002 | — | 71 patents Predictive biomarkers and diagnostics for colorectal cancer therapy response | — |
| 5 | Scil Proteins Generate and optimizing unique proteins for therapeutic and non-therapeutic applications. | $32M | 192 mo ago | Acquired | 54 | 1999 | Henning Afflerbach CEO | 141 patents Engineered ubiquitin-based binding proteins for targeted therapeutic and diagnostic applications | — |
| 6 | Cevec Pharmaceuticals Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system | $28M | 58 mo ago | Acquired | 39 | 2001 | — | 208 patents Production and engineering of viral vectors and glyco-modified recombinant therapeutics. | — |
| 7 | inveox Manufacturing automated laboratory solutions for biopsy sample preparation | $26M | 82 mo ago | Series A | 36 | 2017 | Maria Driesel Co-Founder & CEO | 16 patents Automated histology sample preparation and 3D pathology imaging systems | — |
| 8 | ISAR Bioscience Developer of regenerative medicine | $23M | 31 mo ago | Funding Raised | 19 | 2018 | — | 15 patents Patents concentrated in chemistry & materials | — |
| 9 | GNA Biosolutions Develops instruments, OEM modules and assays for molecular pathogen detection | $20M | 82 mo ago | Series C | 29 | 2010 | — | 96 patents Patents concentrated in chemistry & materials | — |
| 10 | PreOmics Provider of reagents and instruments for proteomics research | $19M | 52 mo ago | Series B | 22 | 2014 | Nils Kulak Co-Founder & CEO | 59 patents Proteomics sample preparation and magnetic protein fractionation for mass spectrometry analysis | 1 job opening |
| 11 | Ayoxxa Biosystems Developer of a platform for multiplex protein analysis | $19M | 113 mo ago | Deadpooled | 40 | 2010 | — | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 12 | Anvajo Provider of point-of-care solutions for laboratory diagnostics | $17M | 43 mo ago | Series A | 66 66 → 50 (-24%) · sector median +19% | 2016 | Stefan Fraedrich Founder | 44 patents Microfluidic sample handling and liquid analysis devices for diagnostics and analytical instrumentation | — |
| 13 | Caprotec Technology platform for proteomics research in biopharma | $15M | 181 mo ago | Acqui-Hired | 11 | 2007 | — | — | — |
| 14 | Icon Genetics Developing biopharmaceuticals and high-value protein products using green plants as production hosts | $15M | 291 mo ago | Acquired | 25 | 1999 | Yuri Gleba Founder & CEO | 326 patents Recombinant virus-like particle vaccines and diagnostic antigens for norovirus and syphilis | — |
| 15 | Proteros Provider of structure-based early-stage drug discovery services and technology platform | $13M | 41 mo ago | Early Stage | 103 103 → 160 (+55%) · sector median +19% | 1999 | Robert Huber Co-Founder | — | — |
| 16 | PL BioScience Manufacturer of human platelet lysate products for cell culture applications | $13M | 22 mo ago | Series A | 13 | 2015 | Hatim Hemeda CEO | 15 patents Patents concentrated in chemistry & materials | 2 launchs · 1 partnership · 1 award |
| 17 | LenioBio Provider of kit for cell-free protein expression for accelerating drug delivery 50Talent top 28%Funding top 37%Moat top 37%Tech top 39% All 10 signals ▾Talenttop 28% Fundingtop 37% Moattop 37% Techtop 39% Patentstop 41% Growthtop 45% Innovationtop 47% Globalbottom 39% Marketbottom 33% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $13.0M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $13M | 10 mo ago | Series A | 18 18 → 44 (+144%) · sector median +19% | 2016 | Remberto Martis Founder & CEO | 20 patents High-throughput membrane protein ligand screening and advanced cell-free protein synthesis platforms | 1 launch · 1 partnership |
| 18 | Miltenyi Biotec Develops tools and products for research and clinical application | $13M | 63 mo ago | Funding Raised | 585 | 1989 | Stefan Miltenyi Founder & MD | 875 patents Advanced cell therapy manufacturing, immune cell engineering, and microfluidic sorting platforms | — |
| 19 | amaxa biosystems Amaxa Biosystems develops and commercializes gene transfer technologies and products. | $12M | 300 mo ago | Acquired | 160 | 1998 | — | — | — |
| 20 | European XFEL Developer of an instrument for imaging biomolecules | $11M | 62 mo ago | Funding Raised | — | 2009 | — | — | — |
| 21 | PreciPoint Developer of digital microscopes and micro-positioning systems | $10M | 46 mo ago | Series A | 37 37 → 44 (+19%) · sector median +19% | 2018 | Dominik Gerber Co-CEO | 43 patents High‑resolution digital microscopy imaging, whole‑slide scanning, image archiving, and distributed analysis | 2 launchs · 1 partnership |
| 22 | Luxendo Manufacturer of light-sheet fluorescence microscopes for 3D bioimaging | $8M | 113 mo ago | Acquired | 20 20 → 14 (-30%) · sector median +19% | 2015 | — | — | 1 award |
| 23 | Neuway Pharma Therapies for the treatment of brain diseases using its proprietary CNS drug delivery platform | $7M | 120 mo ago | Public | 18 | 2014 | — | 33 patents Virus-like particle platforms for mRNA and protein therapeutic delivery | — |
| 24 | Cellbox Solutions Provider of a portable device for cells storage and transport purposes 40Talent top 28%Moat top 38%Funding top 40%Tech top 44% All 11 signals ▾Talenttop 28% Moattop 38% Fundingtop 40% Techtop 44% Growthtop 45% Productbottom 48% Newsbottom 42% Globalbottom 42% Patentsbottom 39% Marketbottom 36% Innovationbottom 35% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 5/10 · IP moat: 11 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $7M | 3 mo ago | Series A | 22 | 2016 | — | 11 patents Automated cell culture incubation devices and methods for bioprocessing | 1 launch · 1 partnership |
| 25 | BioCrea CNS-focused drug development company with a proprietary compound library & patient-derived IPSC (induced… | $7M | 187 mo ago | Deadpooled | — | 2010 | Tom Kronbach CEO | 4 patents Novel heterocyclic pharmacophores for anticonvulsant agents and phosphodiesterase inhibitors | — |
| 26 | Alacris Theranostics Genomics service provider | $7M | 89 mo ago | Funding Raised | 20 20 → 13 (-35%) · sector median +19% | 2009 | Hans Lehrach Founder | 41 patents Molecular diagnostics and biomarker discovery using nanotech optical detection and therapy efficacy assays | — |
| 27 | AMW Transdermal drug delivery technologies | $6M | 101 mo ago | Acquired | 78 78 → 99 (+27%) · sector median +19% | 2008 | Wilfried Fischer Founder | 89 patents Controlled-release drug depots and implant delivery apparatus for pharmaceutical applications | — |
| 28 | Subitec Technology for cultivation of micro algae | $6M | 167 mo ago | Series A | 9 | 2000 | Peter Ripplinger CEO | 11 patents Air‑purifying bioreactors that capture pollutants and generate valuable bioproducts | — |
| 29 | Jenlab Developer of multiphoton tomography and fluorescence lifetime imaging microscopy technology | $6M | 59 mo ago | Funding Raised | — | 2017 | Karsten Koenig CEO | 36 patents Multimodal optical imaging, laser dental hard‑tissue machining, and flow‑based tumor cell detection | — |
| 30 | Nexigen Developer of therapies for oncological indications | $6M | 180 mo ago | Deadpooled | 10 | 2007 | — | 24 patents Protein‑peptide interaction detection platforms for antiviral target discovery and therapeutics | — |
| 31 | Dynamic Biosensors Provides solutions for label-free molecular interaction and biophysical analysis | $6M | 45 mo ago | Acquired | 51 51 → 62 (+22%) · sector median +19% | 2011 | — | 33 patents Microfluidic cell immobilization and bubble control for protein‑small molecule biosensing | 1 launch |
| 32 | Scienion Solutions for the genomics and proteomics industry | $6M | 74 mo ago | Acquired | 114 114 → 111 (-3%) · sector median +19% | 2000 | — | 86 patents Microfluidic droplet dispensing and precision sample preparation for analytical instrumentation | 1 launch |
| 33 | Kumovis Developer of 3D-printing systems | $5M | 72 mo ago | Acquired | 20 | 2017 | Sebastian Pammer Co-Founder | 52 patents 3D‑printed orthopedic implants and additive manufacturing hardware for medical device production | — |
| 34 | Cytena Single cell isolation technology | $5M | 86 mo ago | Acquired | 71 71 → 62 (-13%) · sector median +19% | 2014 | Julian Riba CEO | 168 patents Microfluidic lab‑on‑a‑chip devices for centrifugation, actuation, particle detection, and cell monitoring | 1 partnership |
| 35 | TRON Developer of drugs for the treatment of cancer and other severe diseases | $4M | 50 mo ago | Funding Raised | 144 | 2010 | — | — | 1 expansion · 1 award |
| 36 | faCellitate Developer of synthetic coatings and surface technologies for cell culture applications | $4M | 45 mo ago | Seed | 50 | 2019 | Simon Widmaier Co-Founder & Managing Director | 13 patents Cell‑culture surface coating polymers and biocompatible device attachment technologies | 1 partnership |
| 37 | Microfluidic ChipShop Provides microfluidic lab-on-chip systems | $3M | 89 mo ago | Funding Raised | — | 2002 | — | 43 patents Microfluidic fluid handling platforms for sample intake, dispensing, and transport | 1 partnership |
| 38 | Mosaiques Diagnostics Proteomics-based diagnostics | $3M | 72 mo ago | Funding Raised | — | 2002 | Harald Mischak Founder | 149 patents Personalized diagnostic assays for therapy selection and drug candidate evaluation | — |
| 39 | IRUBIS Developer of analytical technology for real-time bioprocess monitoring and analysis | $3M | 21 mo ago | Seed | 15 15 → 20 (+33%) · sector median +19% | 2017 | Lorenz Mirle Co-Founder | 8 patents Optical spectroscopy flow cells and disposable bioreactors for bioprocess monitoring | — |
| 40 | SenseUP Developer of microbial production strains 21Talent top 35%Moat top 38%Patents top 49%Funding bottom 45% All 7 signals ▾Talenttop 35% Moattop 38% Patentstop 49% Fundingbottom 45% Globalbottom 40% Innovationbottom 37% Marketbottom 23% Talent: 4 named leaders on record Moat: Editorial + unicorn rating 5/10 · IP moat: 14 patents rank vs industry peers · Fliar Intelligence Index 21/100 | $3M | 12 mo ago | Seed | 10 10 → 13 (+30%) · sector median +19% | 2015 | Gunter Festel Co-Founder | 14 patents RNA synthesis platforms and aptamer‑based biosensors for diagnostic protein detection | — |
| 41 | Multi Channel Systems Tools for Electrophysiology | $3M | 60 mo ago | Acquired | 68 | 1996 | Karl-Heinz Boven CEO | — | — |
| 42 | Mo:re Developer of 3D cell culture robot for medical research | $2M | 14 mo ago | Seed | — | 2023 | David Hackenberger Co-Founder | — | 2 launchs · 1 partnership |
| 43 | c-LEcta Specializes in the discovery and production of enzymes & microbial strains for industrial applications | $2M | 41 mo ago | Acquired | 100 100 → 79 (-21%) · sector median +19% | 2004 | — | 163 patents Enzyme technologies for carbohydrate conversion and acrylamide removal in food processing. | 3 job openings · 1 partnership |
| 44 | TissUse Developer of a multi-organ chip platform for tissue culture | $2M | 60 mo ago | Funding Raised | 31 31 → 38 (+23%) · sector median +19% | 2010 | Reyk Horland CEO | 83 patents Microfluidic multi‑organ‑on‑a‑chip platforms for iPSC‑derived tissue modeling | — |
| 45 | Aquarray Provider of droplet microarray technology for clinical application | $2M | 52 mo ago | Funding Raised | 8 | 2018 | Simon Widmaier CEO | 2 patents Optical detection methods for analyzing liquids and their components | — |
| 46 | ASA Spezialenzyme Biotechnology solutions for a wide range of industrial applications | $2M | 38 mo ago | Funding Raised | — | 1991 | — | — | — |
| 47 | Cellendes Biomimetic hydrogel materials for cell culture applications | $2M | 44 mo ago | Funding Raised | — | 2009 | Brigitte Angres Co-Founder & Managing Director | 9 patents Hydrogel matrices and cleavable crosslinkers for pancreatic organoid culture | — |
| 48 | DNTOX Provider of animal-free testing services focused on neurotoxicity and model development 16AI top 45%Talent bottom 49%Funding bottom 48%Global bottom 29% All 5 signals ▾AItop 45% Talentbottom 49% Fundingbottom 48% Globalbottom 29% Marketbottom 22% AI: Product described with: artificial intelligence Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 16/100 | $2M | 35 mo ago | Seed | 8 | 2022 | Kristina Bartmann Co-Founder | — | — |
| 49 | Baseclick Holders of rights to new procedures in click chemistry and DNA photography. | $1M | 44 mo ago | Series B | 14 14 → 10 (-29%) · sector median +19% | 2008 | — | 119 patents Click‑chemistry platforms for modified mRNA synthesis and vaccine development | — |
| 50 | CASCAT Develops fine chemicals using bioprocess | $968K | 29 mo ago | Funding Raised | — | 2014 | Andre Pick Founder & Co-CEO | 19 patents Patents concentrated in chemistry & materials | — |
Top 12 Life Sciences Platforms and Tools companies in Germany
#1
Series A · Lubeck, Schleswig-holstein · founded 2016 · 22 employees$7Mraised▾
Provider of a portable device for cells storage and transport purposes. The company's product Cellbox is a self-sustaining carbon dioxide incubator supporting the appropriate storage, reproduction, transportation and analysis of biologic materials.
- Mar 2026Series A$4.1M
- Oct 2023Grant (prize money)$2.6M
- Jul 2023Series A—
- Jul 2023Grant (prize money)$2.7M
#2
Series A · Dusseldorf, North Rhine Westphalia · founded 2016 · 18 employees$13Mraised▾
Provider of kit for cell-free protein expression for accelerating drug delivery. The company develops ALiCE is the first eukaryotic cell-free protein expression platform for the discovery, development, and production of difficult-to-express proteins. It has active energy regeneration and has components necessary for protein folding, disulfide bonding, and glycosylation.
- Jul 2025Grant (prize money)$4.3M
- Sep 2023Grant (prize money)—
- May 2022Grant (prize money)$2.9M
- Feb 2022Grant (prize money)$56.3K
#3
Seed · Julich, North Rhine Westphalia · founded 2015 · 10 employees$2.7Mraised▾
SenseUp is a developer of microbial production strains. The company uses patented meta sensor technology to screen strains of bacteria, with higher productivity. The technology has applications for train development, SNP identification, library screening, and process dynamics analysis. It also offers a product like amino acids, proteins and peptides, RNA and other natural products.
- May 2025Seed$2.7M
#4
Series A · Aachen, North Rhine Westphalia · founded 2015 · 13 employees$13Mraised▾
Manufacturer of human platelet lysate products for cell culture applications. The company offers a range of platelet lysate products with different safety grades. These products support cell expansion for research, therapeutics, and clinical applications. The company's technology aims to provide solutions for cell culture needs.
- Aug 2024Series A$8.5M
- May 2021Series A$4.5M
#5
Seed · Hamburg, Hamburg · founded 2023$2.5Mraised▾
Developer of 3D cell culture robot for medical research. It offers robotic and software platform for automated and AI-assisted cultivation processes forcell survival and standardisation for research publications and regulatory approval. It is used for cell therapy, drug development, screening, genetic engineering, and others.
- Mar 2025Seed$2.5M
#6
Seed · Munich, Bavaria · founded 2017 · 15 employees$3.3Mraised▾
Developer of analytical technology for real-time bioprocess monitoring and analysis. It offers solutions for proteins, excipients, and nucleic acids in downstream processing. The technology provides real-time data, enabling faster decision-making and simplified bioprocess development. It utilizes mid-infrared spectroscopy for precise measurements and single-use flow cells to minimize contamination risks.
- Aug 2024Seed—
- Oct 2022Seed$2.8M
- Mar 2022Seed$550.4K
- May 2020Grant (prize money)$1.5M
#7
Funding Raised · Planegg, Bavaria · founded 2018 · 19 employees$23.1Mraised▾
ISAR Bioscience is the developer of regenerative medicine. The company uses the induced pluripotent stem cell and genome engineering technologies for developing regenerative medicine. It has collaboration with ldc and Assay.Works to develops therapeutic and discovery technology.
- Nov 2023Grant (prize money)$1M
- Grant (prize money)$22.1M
#8
Series B · Hagen, North Rhine Westphalia · founded 2018$84.5Mraised▾
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis. It offers a product portfolio that includes instruments, microfluidic devices, reagents, software analysis, and database solutions that facilitate high-throughput single-cell analysis. It also, offers single cell sequencing services.
- Nov 2021Series B—
- Dec 2020Series A$30M
- Nov 2020Series A$10M
- Sep 2020Series A$30M
#9
Acquired · Cologne, North Rhine Westphalia · founded 2001 · 39 employees$28.4Mraised▾
Provider of glyco-optimized human cell lines and gene therapy vectors using proprietary cell expression system. The company has ELEVECTA technology for AAV manufacturing, CAP Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. Provides the CAP GT expression platform, a scalable production system for gene therapy vectors. Also offers cell line development and protein expression services.
- Jul 2021Series E—
- Apr 2019Series D—
- Jul 2015Series C$4.9M
- Oct 2012Series C$3.6M
#10
Early Stage · Germany · founded 1999 · 103 employees$13.2Mraised▾
Provider of structure-based early-stage drug discovery services and technology platform. The company offers services for technically challenging drug targets. It supports clients in reaching results and accelerating research timelines. The company provides protein science, biologics, biophysics, and screening assays.
- Jan 2023Unattributed—
- Aug 2012Unattributed$6.2M
- Aug 2007Unattributed$7M
#11
Series A · Dresden, Saxony · founded 2016 · 66 employees$17.3Mraised▾
Provider of point-of-care solutions for laboratory diagnostics. The company offers a free desktop application called the anvajo datalab for scientists to access measurement data acquired with the fluidlab R-300.
- Oct 2022Series A$17.3M
- Jun 2016Seed—
#12
Acquired · Planegg, Bavaria · founded 1999 · 41 employees$71.3Mraised▾
Discovering drug targets through Deductive Genomics. The company has developed complementary biomedical technologies for both drug discovery and drug target validation. Ingenium has developed several drug discovery approaches based on a unique functional analysis of the mammalian genome at the organism level (Deductive Genomics). Its product includes NGENOtyping a novel, high-speed, genetics tool for in vivo validation of gene-based drug targets by providing the most rapid pathway to genetic mouse and rat models. The company is founded as a spin-off from the German Human Genome Project, is a subsidiary of the integrated drug development company Probiodrug.
- Apr 2006Series D$11.1M
- Apr 2005Grant (prize money)$1.4M
- Dec 2003Series C$16.9M
- Sep 2000Series B$43.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Germany
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,605 Germany-affiliated papers.
- Heidelberg University245
- German Cancer Research Center123
- Charité - Universitätsmedizin Berlin95
- Goethe University Frankfurt94
- Ludwig-Maximilians-Universität München91
- Genome13→106
- Gene16→108
- Transcriptome6→61
- Epigenetics2→40
- Context (archaeology)1→33
- Disease1→62
- Gene3→49
- Immune system1→41
- Transcriptome4→37
- Biomarker1→29
- Disease2→41
- Immune system1→29
- Gene4→24
- Genome2→20
- Cancer1→14
Where bioinformatics is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.